Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Abstract: Many drugs fail in clinical trials due to adverse effects on cardiac electrical function, as measured by an increase in the QT interval in the surface electrocardiogram (ECG). However, there are several limitations associated with the QT interval, including poor sensitivity and specificity in predicting drug-induced arrhythmia. This is a growing concern for both regulatory and pharmaceutical agencies, as it translates into significant socio-economic costs. As a result, there has been a growing interest in identifying alternative biomarkers of drug-induced arrhythmia. Studies of the electrophysiological mechanisms underlying drug-induced arrhythmia have identified the morphology of the T-wave as a potential indicator of proarrhythmic activity. A plethora of new T-wave morphology based biomarkers have been proposed recently. This article presents a comprehensive review of the recently published biomarkers of drug-induced arrhythmia based on T-wave morphology. © 2011 Elsevier Ltd.

Original publication




Conference paper

Publication Date





278 - 284